摘要
目的：探讨水飞蓟宾联合阿托伐他汀治疗非酒精性脂肪性肝病（nonalcoholic fatty liver disease，NAFLD）合并高胆固醇血症76例临床观察的临床疗效及不良反应。方法：选择我院2011年6月～2013年10月收治的NAFLD患者同时合并高胆固醇血症76例。在进行生活方式干预（健康教育＋饮食＋运动）的基础上，同时口服水飞蓟宾（70mg，每天3次）和阿托伐他汀（10mg，每晚），疗程3个月。治疗前后检测血清酶学（ALT、AST）、总胆红素（TBIL）、总胆固醇（TC）、人体质量指数（BMI），同时观察治疗期间的不良反应。结果：治疗结束时，谷丙转氨酶（ALT）、谷草转氨酶（AST）及总胆固醇（TC）等均明显下降（P〈0．05）。人体质量指数（BMI）治疗前后也有下降（P〉0．05）。总有效率为86．8％，观察期间2例（2．6％）出现异常反应而终止，给予相应治疗后很快恢复，余均未出现明显不良反应。结论：水飞蓟宾联合阿托伐他汀治疗NAFLD合并高胆固醇血症治疗非酒精性脂肪肝有良好的效果并且是安全的。
Objective： To evaluate the efficacy and safety of silymarin capsules with atorvastatin in the treatment of nonalcoholic t^ttty liver disease （NAFLD） with hypercholesterolemia. Methods： A total of 76 patients with NAFLD with hypercholesterolemia were involved in this study and received the therapy of silymarin capsules with atorvastatin. The life style of every subject was intervened to exercise for 40 min every day for 5 day every week. In addition, the subjects of the trial group were treated with silymarin capsules at a dose of 70 mg three times daily and atorvastatin at 10mg one time. The therapeutic effects were evaluated by examining ALT, AST, TC, TBIL and body mass index （ BMI ）. Results： A significant improvement in ALT, AST and TC was achieved at 3 months after the treatment compared with baseline values （ P 〈0. 05 ）. And the degree of BMI was improved （ P 〉0.05 ）, too. The total effective rate was 86.8% ,the total incidence of adverse reactions was 2.6%. Conclusion ： The clinical curative effect of silymarin capsules with atorvastatin in treatment of NAFLD is distinct, and has less adverse reactions, is worthy of popularization and application.
出处
《中国伤残医学》
2014年第17期25-27,共3页
Chinese Journal of Trauma and Disability Medicine
